Dechra acquires exclusive license from Hassinger Biomedical for Equine ProVet APC ™ – The Horse

Dechra Veterinary Products is pleased to announce the acquisition of the veterinary marketing and distribution rights for the ProVet APC ™ (Autologous Platelet Concentrate) and ProVet BMC ™ (Bone Marrow Concentrate) systems from Hassinger Biomedical. These two patented medical devices concentrate platelets or bone marrow in 90 seconds with a treatment time of 2.5 minutes from start to finish.

The ProVet APC System is a revolutionary device and is arguably the fastest and most transportable platelet concentrator available for the veterinary industry with a total weight of less than 3 pounds. Some of the features of the system include the ability to isolate approximately 90% of the platelets and growth factors available, providing the highest level of reproducibility with a low coefficient of variance of 3.5% and a 97% reduction in the number of Red cells.

ProVet APC’s proprietary technology consistently delivers 6-8ml of a 7.8-fold high concentration of platelet rich plasma and healing concentrate derived from 54ml of whole blood into the 60ml system.

Mike Eldred, President of Dechra North America, said: “The medical industry has long recognized that harnessing the growth factors present in platelets positively improves healing outcomes and reduces recovery time from soft tissue damage. . These two products will be great additions to our equine product line and will further strengthen our position in the regenerative veterinary medicine market ”.

“ProVet APC has become the most sought-after regeneration system for equine athletes,” said Amy Hassinger, CEO of Hassinger Biomedical. “We believe Dechra is uniquely positioned, with its experience in the veterinary industry, to meet the growing global demand from veterinarians and their customers for the ProVet APC and BMC Regenerative Therapy Systems. “

This addition of Provet APC products to Dechra’s equine portfolio will complement our industry-leading Orthokine® Vet irap joint therapy and provide veterinarians with a single partner for their regenerative medicine needs.

About Dechra

Dechra Veterinary Products, located in Overland Park, Kansas, is the US sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal health market. Dechra’s equine product line includes Osphos® (injection of clodronate), Orthokine® vet irap 10 and 60, Osteokine® (PRP), Equidon® (domperidone) Gel, the Vetivex® range of parenteral fluids, Phycox® EQ and a full line of topical dermatological products. The recent addition of Zimeta® (dipyrone injection) further expands Dechra’s equine offering. Dechra Veterinary Products’ companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support and dental care. Our pet brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (suspension for injection of deoxycorticosterone pivalate), Osurnia® (florfenicol-terbinafine-betamethasone acetate), Mirataz® (mirtazapine transdermal ointment), and Phycox® joint health supplements, Porus® One as well as a complete topical dermatological line for veterinary use. For more information, please visit www.dechra-us.com or call (866) 933-2472.

Source link

About Catherine Sherrill

Check Also

Qualitative analysis of key players and competitive industry scenario, 2025

Abstract: The recent study on the Veterinary Welfare market offers a comprehensive review of this …

Leave a Reply

Your email address will not be published. Required fields are marked *